Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NEW U.S. Patent Issued to Dyadic International

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
The Patent is entitled “Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose”.

Dyadic International, Inc. announced today that it has been issued U.S. Patent No. 8,673,618 entitled, "Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose" by the United States Patent and Trademark Office ("USPTO").  

This new patent provides broader intellectual property rights relating to compositions and methods of developing and producing novel enzymes which efficiently convert different sources of plant biomass (e.g. corn stover, wheat straw and bagasse) to fermentable sugars. These sugars can be used in the production of advanced biofuels and bio-based chemicals. 

Methods include processes for degrading plant material using enzyme mixtures and specified enzyme combinations. Enzyme compositions are used to break down specific components of plant biomass (e.g. cellulose, hemi-cellulose, and lignin) into a variety of fermentable sugars.

In addition to claims covering the production of these patented enzymes using Dyadic's C1 Expression System, a wide variety of additional production methods are covered including bacteria, yeast, algae, other fungi and plants.

Dyadic's President and CEO, Mark Emalfarb, stated, "Plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce advanced biofuels and bio-based chemicals. This latest patent further broadens our family of patents that address the advanced biofuels and bio-based chemicals market. This latest patent also expands our comprehensive intellectual property portfolio further protecting our C1 Expression System, and the products derived therefrom.  We anticipate that broadening our rights for these applications will allow us to further attract additional blue chip customers, partners, and collaborators."  





Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dyadic Issued New U.S. Patent
Dyadic International has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office.
Monday, November 11, 2013
Dyadic Welcomes New Chief Operating Officer
Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer.
Friday, May 10, 2013
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!